2023 ESC Guidelines for Infective Endocarditis Management
The 2023 ESC guidelines emphasize a multidisciplinary "Endocarditis Team" approach with key updates in five major areas: expanded antibiotic prophylaxis for high-risk patients, enhanced multimodality imaging for diagnosis, paradigm shift toward partial oral antibiotic therapy in select cases, refined surgical timing recommendations, and structured prevention of recurrence. 1
Core Management Priorities
1. Diagnostic Approach
Blood cultures are mandatory before initiating antibiotics - draw three sets at 30-minute intervals 2. Transesophageal echocardiography (TOE) is essential to confirm clinical stability before transitioning to outpatient or oral therapy 1.
Advanced imaging has been incorporated into diagnostic criteria:
- PET-CT is now included for prosthetic valve endocarditis (PVE) diagnosis, significantly improving detection accuracy 3
- Multimodality imaging is reinforced for both cardiac and extracardiac assessment 4
2. Antimicrobial Therapy
Empirical Treatment Strategy
Treatment must start promptly after blood cultures are obtained. The empirical regimen depends on three factors 2:
For community-acquired native valve or late PVE (≥12 months post-surgery):
- Ampicillin 12 g/day IV in 4-6 doses PLUS
- (Flu)cloxacillin or oxacillin 12 g/day IV in 4-6 doses PLUS
- Gentamicin 3 mg/kg/day IV/IM in single dose
For penicillin-allergic patients:
- Vancomycin 30-60 mg/kg/day IV in 2-3 doses PLUS
- Gentamicin 3 mg/kg/day IV/IM in single dose
For early PVE (<12 months) or healthcare-associated IE:
- Vancomycin 30 mg/kg/day IV in 2 doses PLUS
- Gentamicin 3 mg/kg/day IV/IM in single dose PLUS
- Rifampin 900-1200 mg IV/orally in 2-3 doses (start 3-5 days after vancomycin/gentamicin) 2
Organism-Specific Regimens
HACEK organisms:
- Ceftriaxone 2 g/day for 4 weeks (native valve) or 6 weeks (PVE) is the standard treatment 2
- Alternative: Ampicillin 12 g/day IV plus gentamicin 3 mg/kg/day for 4-6 weeks if no beta-lactamase production
Non-HACEK Gram-negative bacteria:
- Early surgery PLUS at least 6 weeks of bactericidal beta-lactam/aminoglycoside combinations 2
- Consultation with Endocarditis Team or infectious disease specialist is mandatory given high mortality (>50%)
Blood culture-negative IE specific pathogens 2:
| Pathogen | Treatment | Duration |
|---|---|---|
| Brucella spp. | Doxycycline 200 mg/24h + cotrimoxazole 960 mg/12h + rifampin 300-600 mg/24h orally | ≥3-6 months |
| C. burnetii (Q fever) | Doxycycline 200 mg/24h + hydroxychloroquine 200-600 mg/24h orally | >18 months |
| Bartonella spp. | Doxycycline 100 mg/12h orally (4 weeks) + gentamicin 3 mg/24h IV (2 weeks) | 4-6 weeks total |
| T. whipplei (Whipple's) | Doxycycline 200 mg/24h + hydroxychloroquine 200-600 mg/24h orally | ≥18 months |
Fungal IE:
- Combined antifungal therapy PLUS surgical valve replacement is mandatory 2
- Mortality exceeds 50% without surgery
3. Partial Oral Antibiotic Therapy (POT) - Major 2023 Update
A paradigm shift allows switching to oral antibiotics in carefully selected patients 5, 6, 7:
Eligibility criteria for POT:
- Native valve endocarditis caused by viridans streptococci or Streptococcus bovis 4
- Clinically stable with no complications (no heart failure, no concerning echocardiographic features, no neurological signs, no renal impairment) 2
- Completed initial critical phase (first 2 weeks of IV therapy) 2
- Post-surgical patients who received adequate IV therapy ≥7 days after surgery 3
Benefits demonstrated in real-world data:
- Reduced hospital stays and treatment costs 7
- Enhanced quality of life and patient adherence 7
- Fewer IV-related complications 7
- No increase in mortality or treatment failure 7
Critical caveat: POT should NOT be considered during the critical first 2 weeks, or in patients with heart failure, concerning echo findings, neurological complications, or renal impairment 2.
4. Surgical Intervention
Surgery is indicated in approximately 50% of IE patients and is one of the most important protective factors against mortality 1, 3. Failure to operate when indicated markedly worsens survival 1.
Main Surgical Indications 1, 3:
- Heart failure (most common)
- Uncontrolled infection - including resistant organisms (S. aureus, non-HACEK Gram-negatives)
- Prevention of recurrent embolism
Surgical Timing Categories 1, 3:
- Emergency: Within 24 hours (regardless of antibiotic duration)
- Urgent: Within 3-5 days of diagnosis
- Non-urgent: Later than 5 days but within same hospitalization
Delayed intervention increases complication risk significantly 3.
Post-Stroke Surgical Considerations - Updated 2023 3:
Embolic (ischemic) stroke should NOT delay surgery once surgical indication is identified - this is a critical update addressing previous hesitation.
Hemorrhagic stroke: Surgery may be delayed up to 4 weeks depending on clinical condition, but this must be individualized based on the severity of both the stroke and the IE 3.
Device-Related IE:
Complete CIED removal is mandatory for CIED-associated endocarditis - conservative treatment increases mortality 1, 3. For patients with uninfected left-sided prosthetic valves and CIED infection, complete removal plus prolonged antibiotics may prevent left-sided valve infection 1.
Early PVE (<6 months post-surgery): Requires urgent surgical intervention, particularly with S. aureus or non-HACEK Gram-negative bacteria 3. However, the Dutch IE Working Group advises caution regarding the new ESC class I recommendation for surgery in all early PVE cases 4.
5. Endocarditis Team Approach
All patients with suspected or confirmed IE should be managed by a specialized multidisciplinary Endocarditis Team 1, 5, 3. This team-based approach has been shown to improve diagnosis, optimize treatment decisions, and enhance outcomes.
The team should include:
- Cardiologists
- Cardiac surgeons
- Infectious disease specialists
- Imaging specialists
- Microbiologists
Management should occur in designated Heart Valve Centres for complicated cases, with referral centres managing uncomplicated cases 5. Continuous data sharing between these centers is essential.
6. Prevention and Long-Term Management
Antibiotic Prophylaxis - Expanded in 2023 5, 6:
High-risk patients requiring prophylaxis:
- Previous IE
- Prosthetic heart valves
- Cyanotic congenital heart disease
- Cardiac transplant recipients with valvulopathy
The 2023 guidelines expanded prophylaxis recommendations to include intermediate-risk patients in certain scenarios 5.
Recurrence Prevention 1:
Patients with previous IE require structured surveillance:
- Education about preventative measures and immediate medical evaluation for fever/chills
- Mandatory good oral health maintenance and skin hygiene
- Timely and curative antibiotic therapy for all bacterial infections
- Proper patient and caregiver education on self-monitoring
Common pitfall: Inadequate patient education about IE recurrence risk leads to delayed presentation with subsequent episodes.
7. Outpatient Parenteral Antibiotic Therapy (OPAT)
OPAT can be considered after the critical first 2 weeks in select patients 2:
Requirements for OPAT:
- Medical stability achieved
- No heart failure, concerning echo features, neurological signs, or renal impairment
- Patient education completed
- Regular post-discharge evaluation: nurses daily, physician 1-2 times weekly
- Physician-directed program (not home-infusion model)
Preferred for: Oral streptococci or S. bovis, native valve, stable patient, no complications 2.
Key Implementation Priorities for Resource-Limited Settings
The 2025 implementation guidance for low-resource settings emphasizes 1:
- Early blood culture collection before antibiotics
- TOE confirmation of stability before discharge
- Surgical treatment as integral component (despite resource constraints)
- Patient education on recurrence prevention
- Structured long-term surveillance
Critical Practice Points
- Never delay blood cultures - three sets at 30-minute intervals before any antibiotics
- Surgery should not be delayed for ischemic stroke when surgical indication exists
- Complete device removal is non-negotiable for CIED-IE
- POT is now acceptable in select stable patients with native valve streptococcal IE after initial IV therapy
- Endocarditis Team consultation is mandatory for blood culture-negative IE, non-HACEK Gram-negatives, and all complicated cases
- Failure to operate when indicated is associated with markedly worse survival